BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 36878807)

  • 21. Fecal immunochemical test in colorectal cancer screening: Colonoscopy findings by different cut-off levels.
    Ribbing Wilén H; Blom J; Höijer J; Hultcrantz R
    J Gastroenterol Hepatol; 2019 Jan; 34(1):103-112. PubMed ID: 29968937
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel Stool-Based Protein Biomarkers for Improved Colorectal Cancer Screening: A Case-Control Study.
    Bosch LJW; de Wit M; Pham TV; Coupé VMH; Hiemstra AC; Piersma SR; Oudgenoeg G; Scheffer GL; Mongera S; Sive Droste JT; Oort FA; van Turenhout ST; Larbi IB; Louwagie J; van Criekinge W; van der Hulst RWM; Mulder CJJ; Carvalho B; Fijneman RJA; Jimenez CR; Meijer GA
    Ann Intern Med; 2017 Dec; 167(12):855-866. PubMed ID: 29159365
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk stratification for advanced colorectal neoplasia according to fecal hemoglobin concentration in a colorectal cancer screening program.
    Auge JM; Pellise M; Escudero JM; Hernandez C; Andreu M; Grau J; Buron A; López-Cerón M; Bessa X; Serradesanferm A; Piracés M; Macià F; Guayta R; Filella X; Molina R; Jimenez W; Castells A;
    Gastroenterology; 2014 Sep; 147(3):628-636.e1. PubMed ID: 24937264
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fecal immunochemical test in cancer screening - colonoscopy outcome in FIT positives and negatives.
    Ribbing Wilén H; Blom J; Höijer J; Andersson G; Löwbeer C; Hultcrantz R
    Scand J Gastroenterol; 2019 Mar; 54(3):303-310. PubMed ID: 30907196
    [No Abstract]   [Full Text] [Related]  

  • 25. Colonoscopy vs. Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer (CONFIRM): Rationale for Study Design.
    Dominitz JA; Robertson DJ; Ahnen DJ; Allison JE; Antonelli M; Boardman KD; Ciarleglio M; Del Curto BJ; Huang GD; Imperiale TF; Larson MF; Lieberman D; O'Connor T; O'Leary TJ; Peduzzi P; Provenzale D; Shaukat A; Sultan S; Voorhees A; Wallace R; Guarino PD
    Am J Gastroenterol; 2017 Nov; 112(11):1736-1746. PubMed ID: 29016565
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk-stratified selection to colonoscopy in FIT colorectal cancer screening: development and temporal validation of a prediction model.
    Thomsen MK; Pedersen L; Erichsen R; Lash TL; Sørensen HT; Mikkelsen EM
    Br J Cancer; 2022 May; 126(8):1229-1235. PubMed ID: 35058592
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Diagnostic Performance of Fecal Immunochemical Tests for Detecting Advanced Neoplasia at Surveillance Colonoscopy.
    Berwald G; Young GP; Cock C; Bampton P; Fraser R; Symonds EL
    Clin Gastroenterol Hepatol; 2024 Apr; 22(4):878-885.e2. PubMed ID: 37743036
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Switching from guaiac to immunochemical faecal occult blood test increases participation and diagnostic yield of colorectal cancer screening.
    Bretagne JF; Piette C; Cosson M; Durand G; Lièvre A
    Dig Liver Dis; 2019 Oct; 51(10):1461-1469. PubMed ID: 31151896
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combining risk factors with faecal immunochemical test outcome for selecting CRC screenees for colonoscopy.
    Stegeman I; de Wijkerslooth TR; Stoop EM; van Leerdam ME; Dekker E; van Ballegooijen M; Kuipers EJ; Fockens P; Kraaijenhagen RA; Bossuyt PM
    Gut; 2014 Mar; 63(3):466-71. PubMed ID: 23964098
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adding family history to faecal immunochemical testing increases the detection of advanced neoplasia in a colorectal cancer screening programme.
    Kallenberg FG; Vleugels JL; de Wijkerslooth TR; Stegeman I; Stoop EM; van Leerdam ME; Kuipers EJ; Bossuyt PM; Dekker E
    Aliment Pharmacol Ther; 2016 Jul; 44(1):88-96. PubMed ID: 27170502
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population screening for colorectal cancer means getting FIT: the past, present, and future of colorectal cancer screening using the fecal immunochemical test for hemoglobin (FIT).
    Allison JE; Fraser CG; Halloran SP; Young GP
    Gut Liver; 2014 Mar; 8(2):117-30. PubMed ID: 24672652
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serological biomarkers in triage of FIT-positive subjects?
    Nielsen HJ; Christensen IJ; Andersen B; Rasmussen M; Friis-Hansen LJ; Bygott T; MiCallef J;
    Scand J Gastroenterol; 2017; 52(6-7):742-744. PubMed ID: 28271924
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New fecal bacterial signature for colorectal cancer screening reduces the fecal immunochemical test false-positive rate in a screening population.
    Malagón M; Ramió-Pujol S; Serrano M; Amoedo J; Oliver L; Bahí A; Miquel-Cusachs JO; Ramirez M; Queralt-Moles X; Gilabert P; Saló J; Guardiola J; Piñol V; Serra-Pagès M; Castells A; Aldeguer X; Garcia-Gil LJ
    PLoS One; 2020; 15(12):e0243158. PubMed ID: 33259546
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Colonoscopy Versus Fecal Immunochemical Test for Reducing Colorectal Cancer Risk: A Population-Based Case-Control Study.
    Kim SY; Kim HS; Kim YT; Lee JK; Park HJ; Kim HM; Kang DR
    Clin Transl Gastroenterol; 2021 Apr; 12(5):e00350. PubMed ID: 33928919
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know.
    Tinmouth J; Lansdorp-Vogelaar I; Allison JE
    Gut; 2015 Aug; 64(8):1327-37. PubMed ID: 26041750
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A quantitative immunochemical fecal occult blood test for colorectal neoplasia.
    Levi Z; Rozen P; Hazazi R; Vilkin A; Waked A; Maoz E; Birkenfeld S; Leshno M; Niv Y
    Ann Intern Med; 2007 Feb; 146(4):244-55. PubMed ID: 17310048
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The second round of the Dutch colorectal cancer screening program: Impact of an increased fecal immunochemical test cut-off level on yield of screening.
    Kooyker AI; Toes-Zoutendijk E; Opstal-van Winden AWJ; Spaander MCW; Buskermolen M; van Vuuren HJ; Kuipers EJ; van Kemenade FJ; Ramakers C; Thomeer MGJ; Dekker E; Nagtegaal ID; de Koning HJ; van Leerdam ME; Lansdorp-Vogelaar I
    Int J Cancer; 2020 Aug; 147(4):1098-1106. PubMed ID: 31853977
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Can a biomarker triage test reduce colonoscopy burden in fecal immunochemical test screening?
    Greuter MJ; Carvalho B; Wit M; Dekker E; Spaander MC; Meijer GA; Engeland MV; Coupé VM
    J Comp Eff Res; 2020 Jun; 9(8):563-571. PubMed ID: 32462913
    [No Abstract]   [Full Text] [Related]  

  • 39. Effect of Sex, Age, and Positivity Threshold on Fecal Immunochemical Test Accuracy: A Systematic Review and Meta-analysis.
    Selby K; Levine EH; Doan C; Gies A; Brenner H; Quesenberry C; Lee JK; Corley DA
    Gastroenterology; 2019 Dec; 157(6):1494-1505. PubMed ID: 31472152
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Positive predictive values of fecal immunochemical tests used in the STOP CRC pragmatic trial.
    Nielson CM; Petrik AF; Jacob L; Vollmer WM; Keast EM; Schneider JL; Rivelli JS; Kapka TJ; Meenan RT; Mummadi RR; Green BB; Coronado GD
    Cancer Med; 2018 Sep; 7(9):4781-4790. PubMed ID: 30101513
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.